Abstract:Widespread use of contemporary antiretroviral therapy globally has transformed HIV disease into a chronic illness associated with excess risk for disorders of the heart and circulatory system. Current clinical care and research has focused on improving HIV-related cardiovascular disease outcomes, survival, and quality of life. In high-income countries, emphasis on prevention of atherosclerotic coronary artery disease over the past decade, including aggressive management of traditional risk factors and earlier initiation of antiretroviral therapy, has reduced risk for myocardial infarction among persons living with human immunodeficiency virus-1 infection. Still, across the globe, persons living with human immunodeficiency virus-1 infection on effective antiretroviral therapy treatment remain at increased risk for ischemic outcomes such as myocardial infarction and stroke relative to the persons without HIV. Unique features of HIV-related cardiovascular disease, in part, include the pathogenesis of coronary disease characterized by remodeling ectasia and unusual plaque morphology, the relative high proportion of type 2 myocardial infarction events, abnormalities of the aorta such as aneurysms and diffuse aortic inflammation, and HIV cerebrovasculopathy as a contributor to stroke risk. Literature over the past decade has also reflected a shift in the profile and prevalence of HIV-associated heart failure, with a reduced but persistent risk of heart failure with reduced ejection fraction and a growing risk of heart failure with preserved ejection fraction. Cardiac magnetic resonance imaging and autopsy data have emphasized the central importance of intramyocardial fibrosis for the pathogenesis of both heart failure with preserved ejection fraction and the increase in risk of sudden cardiac death. Still, more research is needed to better characterize the underlying mechanisms and clinical phenotype of HIV-associated myocardial disease in the current era. Across the different cardiovascular disease manifestations, a common pathogenic feature is that HIV-associated inflammation working through different mechanisms may amplify underlying pathology because of traditional risk and other host factors. The prevalence and phenotype of individual cardiovascular disease manifestations is ultimately influenced by the degree of injury from HIV disease combined with the profile of underlying cardiometabolic factors, both of which may differ substantially by region globally.

Evolving mechanisms and presentations of cardiovascular disease in people with HIV: implications for management

Prevention and treatment of cardiovascular disease in HIV: practical insights in an evolving field

Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context

Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management

Progressin the Study of Antiretroviral Therapy Related Cardiovascular Diseases in AIDS Patients

Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review

Higher cardiovascular disease risks in people living with HIV: A systematic review and meta-analysis

Cardiovascular Disease Risk Factor Control in People With and Without Human Immunodeficiency Virus

HIV infection and coronary heart disease: mechanisms and management

Cardiac and Renal Comorbidities in Aging People Living With HIV

Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease

Primary Prevention of Cardiovascular Disease for People Living with Human Immunodeficiency Virus

HIV-Associated Cardiovascular Disease Pathogenesis: An Emerging Understanding Through Imaging and Immunology

Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations

Cardiovascular challenges in the era of antiretroviral therapy for AIDS/ HIV: A comprehensive review of research advancements, pathophysiological insights, and future directions

Cardiac adiposity as a modulator of cardiovascular disease in HIV

Current Scenario and Strategies to Tackle Cardiovascular Disease Risk in HIV Geriatrics

Features of cardiovascular disease in low-income and middle-income countries in adults and children living with HIV

Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis

HIV, HIV-specific Factors and Myocardial Disease in Women

Coronary Microvascular Dysfunction is Present Among Well-Treated Asymptomatic Persons with HIV and Similar to Those with Diabetes